ifosfamide

P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2028 --> Sep 2027

The patient received neoadjuvant chemotherapy with VDC (vincristine, doxorubicin, cyclophosphamide) and PIE (cisplatin, ifosfamide, etoposide) regimens, followed by surgical resection, adjuvant chemotherapy, and pelvic radiotherapy. This case underscores the importance of including Ewing sarcoma in the differential diagnosis of rapidly growing cervical tumors, particularly in young women. A multidisciplinary approach involving early molecular diagnostics and aggressive combined therapy is critical to improving clinical outcomes in such rare and aggressive cases.

P2, N=406, Not yet recruiting, Milton S. Hershey Medical Center

Radiation-associated laryngeal angiosarcoma is exceptionally rare and portends a poor prognosis. This case illustrates the potential value of genomically informed multimodal therapy integrating chemotherapy, immunotherapy, and targeted agents; in our patient, toripalimab plus gemcitabine/nab-paclitaxel achieved a 9-month partial response. Further studies are needed to establish evidence-based treatment strategies for this understudied disease.

P1/2, N=56, Terminated, Antengene Corporation | Active, not recruiting --> Terminated; Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study

The patient underwent a modified radical mastectomy and three cycles of postoperative systemic chemotherapy with a combination of ifosfamide and cisplatin, which was well-tolerated. This case highlights the progression of PTB from benign to malignant and suggests that elevated Ki-67 and abnormalities in MDM2/p53 could serve as potential molecular markers. For patients with multiple recurrences or heterogeneous PTB components, individualized treatment strategies are recommended, with reference to soft tissue sarcoma protocols to optimize prognosis.

P2, N=16, Completed, Seoul National University Hospital | Active, not recruiting --> Completed | N=34 --> 16

Following multidisciplinary discussion, the patient was initiated on adjuvant chemotherapy using the CAV-IE (cyclophosphamide, doxorubicin, vincristine alternating with ifosfamide and etoposide), with a plan to complete 12 cycles, while radiotherapy was not indicated. She commenced her treatment with Cycle 1 of the IE component, accompanied by supportive care including intravenous fluids, ondansetron, omeprazole, and dexamethasone...She developed dysuria during hospitalization, and the treatment plan was adjusted to include an increased dose of mesna to enhance uroprotection. This case highlights the importance of considering EES in the differential diagnosis of persistent soft tissue masses, even in slow-growing lesions. It underscores the pivotal role of immunohistochemistry and multidisciplinary management in achieving a definitive diagnosis and favorable outcomes.

In vitro we identified that romidepsin synergizes with doxorubicin and etoposide and that it increases the efficacy of the standard of care combinations VDC/IE. In vivo, the combination of romidepsin and ifosfamide/etoposide (IE) leads to a significant decrease in tumor volume compared to that of IE alone. Our data indicates that romidepsin improves efficacy of chemotherapeutic agents in vitro and leads to a decreased tumor volume in vivo, suggesting that the addition of romidepsin may improve upfront treatment in ES patients.

The patient underwent chemotherapy with epirubicin and ifosfamide but experienced recurrence with lymph node and peritoneal involvement and succumbed to the disease after 9 months. Moreover, it identifies a novel fusion, which may have implications for tumor classification and diagnostic refinement. The morphological findings also suggest a possible association with poor clinical outcomes.

Current chemotherapy treatments, including the TIP (Taxol, Ifosfamide, Cisplatin) regimen, have shown limited effects but strong side effects in advanced Penile squamous cell carcinoma (PSCC) patients. Furthermore, compared with cisplatin, TROP-2 targeted ADC could achieve an equivalent inhibitory effect on the proliferation of PSCC both in vivo and in vitro. TROP-2 promoted PSCC cell proliferation via AKT/PKCα-dependent pathway, and TROP-2-targeted ADC-drug has a gratifying inhibitory effect on PSCC proliferation both in vivo and in vitro.

P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026